Last reviewed · How we verify

Oxbryta — Competitive Intelligence Brief

Oxbryta (voxelotor) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemoglobin S polymerization inhibitor. Area: Hematology.

discontinued Hemoglobin S polymerization inhibitor Hemoglobin S (HbS) Hematology Live · refreshed every 30 min

Target snapshot

Oxbryta (voxelotor) — Global Blood Theraps. Voxelotor inhibits HbS polymerization by increasing oxygen affinity, potentially reducing RBC sickling and improving deformability.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oxbryta TARGET voxelotor Global Blood Theraps discontinued Hemoglobin S polymerization inhibitor Hemoglobin S (HbS) 2019-01-01
Oxbryta Voxelotor Pfizer Inc. marketed Hemoglobin S polymerization inhibitor Hemoglobin S (HbS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemoglobin S polymerization inhibitor class)

  1. Global Blood Theraps · 1 drug in this class
  2. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxbryta — Competitive Intelligence Brief. https://druglandscape.com/ci/voxelotor. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: